Latest market price
18.68
+0.31+1.69%
MIRQT31Mirion Technologies, Inc.·NYSE
18.68+1.69%
TA
Loading chart...
Screen all →
Snapshot
Index—P/E169.82EPS (ttm)0.11Insider Own33.90%Shs Outstand243.28MPerf Week25.20%
Market Cap4.54BForward P/E28.22EPS next Y0.66Insider Trans0.01%Shs Float223.78MPerf Month27.95%
Enterprise Value5.36BPEG8.19EPS next Q0.21Short Float18.41%Perf Quarter15.52%
Income29.00MP/S4.21EPS this Y10.95%Short Ratio10.12Perf Half Y-7.34%
Sales1.08BP/B2.48EPS next Y22.48%ROA0.83%Short Interest41.19MPerf YTD-20.24%
Book/sh7.55P/C10.92EPS next 5Y20.74%ROE1.59%52W High29.83 -37.38%Perf Year-35.65%
Cash/sh1.71P/FCF26.73EPS past 3/5Y—ROIC1.51%52W Low14.04 33.05%Perf 3Y171.91%
Dividend Est.—EV/EBITDA23.43Sales past 3/5Y8.81% —Gross Margin48.07%Volatility6.67% 4.97%Perf 5Y77.90%
Dividend TTM—EV/Sales4.97EPS Y/Y TTM-6.42%Oper. Margin5.96%ATR (14)0.83Perf 10Y—
Dividend Ex-Date—Quick Ratio2.49Sales Y/Y TTM19.73%Profit Margin2.69%RSI (14)69.99Recom2.11
Dividend Gr. 3/5Y—Current Ratio3.02EPS Q/Q0.00%SMA2015.71%Beta1.06Target Price23.00
Payout0.00%Debt/Eq0.67Sales Q/Q24.66%SMA5018.59%Rel Volume1.36Prev Close18.37
Employees3,281LT Debt/Eq0.67EarningsFeb 09SMA2002.37%Avg Volume4.08MPrice18.68
IPO DateAug 20, 2020Option/ShortYes / YesEPS/Sales Surpr.-0.62% 0.89%Net Debt/EBITDA3.58Volume5,528,524Change1.69%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-30-26ReiteratedGoldman SachsBuy$23 → $20
Sep-03-26InitiatedJefferiesBuy$20
Aug-10-26ReiteratedMorgan StanleyEqual Weight$25 → $23
Jul-30-26ReiteratedNorthland SecuritiesOutperform$29 → $24
Jul-29-26ReiteratedGoldman SachsBuy$25 → $23
Jul-13-26ReiteratedMorgan StanleyEqual Weight$27 → $25
Jul-10-26ReiteratedGoldman SachsBuy$29 → $25
May-04-26ReiteratedEvercore ISI GroupOutperform$29 → $28
Mar-11-26ReiteratedMorgan StanleyEqual Weight$29 → $27
Feb-13-26ReiteratedRobert W. Baird$30 → $29
Latest News· Times ET
Oct-28-26
Oct-27-26
Oct-26-26
Oct-20-26
Oct-18-26
Oct-15-26
Oct-14-26
Oct-09-26
Oct-06-26
Oct-06-2609:20AM
Oct-01-26
Company

Mirion Technologies, Inc., established in 2005 and formerly known as Global Monitoring Systems, Inc. until its name change in January 2006, is based in Atlanta, Georgia. The company specializes in providing a comprehensive suite of specialized solutions for radiation detection, measurement, analysis, and monitoring. Its operations span a wide international footprint, covering countries such as the United States, Canada, the United Kingdom, France, Germany, Finland, China, Belgium, the Netherlands, Estonia, and Japan. The business is organized into two distinct operating segments: Medical and Industrial. The Medical segment delivers critical solutions aimed at enhancing patient safety and treatment accuracy within healthcare environments. Offerings here include quality assurance and dosimetry tools for radiation oncology, specialized patient safety systems for diagnostic imaging and radiation therapy centers, and precision calibration and verification solutions for medical imaging and treatment accuracy. Furthermore, it supplies radionuclide therapy products, which encompass shielding, handling equipment, dedicated medical imaging furniture, and rehabilitation aids for nuclear medicine applications. This segment fundamentally supports advancements in medical diagnostics, cancer treatment, professional safety for practitioners, and patient recovery. Conversely, the Industrial segment addresses vital requirements in radiation safety, measurement, and analysis across non-medical industries. It furnishes clients with personal radiation detection devices, identification equipment, and advanced analytical instrumentation. Mirion's extensive product and solution portfolio includes a variety of items such as nuclear medicine preparations, personal dosimeters, contamination and clearance monitoring systems, and sophisticated reactor instrumentation and control equipment. They also provide both medical and industrial imaging systems along with their related accessories, in addition to specialized instruments for alpha spectroscopy, alpha/beta counting, and gamma spectroscopy detector systems. Supplementary offerings include electrical penetration components, cancer diagnostic tools, software solutions, and a range of other services. Mirion serves a broad and varied clientele across numerous sectors. This includes healthcare providers like hospitals, clinics, urgent care facilities, dental and veterinary offices, and specialized radiation treatment centers, as well as original equipment manufacturers (OEMs) for radiation therapy. Beyond healthcare, their customers extend to research laboratories, military organizations, governmental agencies, various industrial enterprises, power and utility companies, reactor design firms, and nuclear power plants (NPPs).

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1,080925861801—————
Cost of Goods Sold Incl. D&A561487459444—————
Gross Profit519439402357—————
Selling, General and Administrative Excl. Other415348338339—————
Research and Development40393532—————
Other Operating Expense-1047—————
Operating Income655225-22—————
Interest Expense33425862—————
Unusual Expense
—————————
Non-Operating Income (Expense)1123-1-21—————
Net Income Before Taxes4033-34-105—————
Income Taxes933-7—————
Consolidated Net Income2929-36-97—————
Net Income From Continuing Operations3130-37-99—————
Net Income2929-36-97—————
EPS (Recurring)0.120.13-0.18-0.49—————
EPS (Basic, Before Extraordinaries)0.120.13-0.18-0.49—————
EPS (Diluted)0.110.11-0.18-0.49—————
EBITDA229213179149—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio169.82212.91———————
Price To Sales Ratio4.195.824.152.51—————
Gross Margin48.0647.4646.6944.57—————
Operating Margin6.025.622.90-2.75—————
Net Margin2.693.14-4.18-12.11—————
Shares Outstanding242230205196—————
Market Capitalization4,5215,3873,5772,009—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$32.09$27.01$21.93$16.86$11.78● Close Price0.00M2.87M5.74M8.61M11.48MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Schopfer BrianChief Financial OfficerSep 02 '26Buy15.6020,000312,000933,290Sep 02
Moore Christopher A.Chief Accounting Officer (PAO)May 07 '26Sale19.648,400164,97622,157May 08
Kingsley Lawrence DDirectorDec 10 '25Sale24.73350,0008,654,8003,509,075Dec 12
Kingsley Lawrence DDirectorNov 21 '25Sale23.83300,0007,148,4003,900,000Nov 21
Eloy LoicNuclear & Safety PresidentNov 11 '25Sale27.2445,0001,225,68397,770Nov 12
Lee EmmanuelleChief Legal OfficerNov 10 '25Sale27.4112,500342,64384,640Nov 12
Schopfer BrianChief Financial OfficerNov 06 '25Sale27.65100,0002,765,420904,432Nov 10
Logan Thomas DChief Executive OfficerAug 12 '25Sale21.79175,0003,813,6353,567,305Aug 13
Logan Thomas DChief Executive OfficerAug 11 '25Sale21.31325,0006,927,1483,742,305Aug 13
Eloy LoicNuclear & Safety PresidentAug 05 '25Sale21.3022,166472,138142,770Aug 06
Schopfer BrianChief Financial OfficerJun 25 '25Sale21.0075,0001,575,000919,432Jun 27
Schopfer BrianChief Financial OfficerMay 21 '25Sale18.2775,0001,370,003919,432May 23
Kingsley Lawrence DDirectorMay 21 '25Sale17.94500,0008,972,3500May 23
Eloy LoicTechnologies Group PresidentDec 13 '24Sale17.8944,000787,160133,663Dec 17
Lee EmmanuelleChief Legal OfficerOct 31 '24Sale14.273,40548,6030Nov 04
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.